Pharsight

1. Children's Zyrtec Allergy patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6455533	J AND J CONSUMER INC	Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin	Jul, 2018 (5 years ago)

Market Authorisation Date: 30 November, 2020

Treatment: Treatment of seasonal and perennial allergic rhinitis symptoms

Dosage: TABLET, CHEWABLE;ORAL

Strength	Dosage	Availability
5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, CHEWABLE;ORAL	Discontinued
10MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, CHEWABLE;ORAL	Over the counter

CHILDREN'S ZYRTEC ALLERGY family patents

2. Children's Zyrtec Hives Relief patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6455533	J AND J CONSUMER INC	Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin	Jul, 2018 (5 years ago)

Market Authorisation Date: 30 November, 2020

Treatment: Treatment of seasonal and perennial allergic rhinitis symptoms

Dosage: TABLET, CHEWABLE;ORAL

Strength	Dosage	Availability
5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, CHEWABLE;ORAL	Discontinued
10MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET, CHEWABLE;ORAL	Discontinued

CHILDREN'S ZYRTEC HIVES RELIEF family patents

3. Quzyttir patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9180090	JDP	Non-sedating antihistamine injection formulations and methods of use thereof	Feb, 2030 (5 years from now)
US8513259	JDP	Non-sedating antihistamine injection formulations and methods of use thereof	Feb, 2030 (5 years from now)
US9119771	JDP	Non-sedating antihistamine injection formulations and methods of use thereof	Feb, 2030 (5 years from now)
US8263581	JDP	Non-sedating antihistamine injection formulations and methods of use thereof	Feb, 2030 (5 years from now)
US8314083	JDP	Non-sedating antihistamine injection formulations and methods of use thereof	Feb, 2030 (5 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Product(NP)	Oct 04, 2022

Market Authorisation Date: 04 October, 2019

Treatment: Treatment of acute urticaria; Method of increasing peak plasma or onset of plasma concentration by intravenous injection in individuals in need of treatment for acute urticaria; Method of treatment in...

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
10MG/ML (10MG/ML)	SOLUTION;INTRAVENOUS	Prescription

QUZYTTIR family patents

4. Zerviate patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8829005	HARROW EYE	Ophthalmic formulations of cetirizine and methods of use	Mar, 2030 (5 years from now)
US9993471	HARROW EYE	Ophthalmic formulations of cetirizine and methods of use	Mar, 2030 (5 years from now)
US9750684	HARROW EYE	Ophthalmic formulations of cetirizine and methods of use	Mar, 2030 (5 years from now)
US8829005 (Pediatric)	HARROW EYE	Ophthalmic formulations of cetirizine and methods of use	Sep, 2030 (6 years from now)
US9254286	HARROW EYE	Ophthalmic formulations of cetirizine and methods of use	Jul, 2032 (8 years from now)
US9254286 (Pediatric)	HARROW EYE	Ophthalmic formulations of cetirizine and methods of use	Jan, 2033 (8 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Dosage Form(NDF)	May 30, 2020
Pediatric Exclusivity(PED)	Nov 30, 2020

Market Authorisation Date: 30 May, 2017

Treatment: Treatment of ocular itching associated with allergic conjunctivitis

Dosage: SOLUTION/DROPS;OPHTHALMIC